Quarterly guidance

Revenue
$1.22 billion to $1.24 billion
EPS
$1.51 to $1.56
Operating margin
Approximately 25%

Annual guidance

Revenue
$4.64 billion to $4.66 billion
EPS
$5.40 to $5.45
Operating margin
Approximately 23.6% at the high end

Outlook

Clinical growth
Expects mid-teens growth for clinical sequencing consumables in 2026.
Research and applied
Expects mid- to high single-digit declines for research and applied sequencing consumables in 2026.
NovaSeq X conversion
Expects clinical conversion to reach 80% to 85% in coming quarters.
BioInsight
Anticipates the platform will become more visible in 2027.
China
Remains committed to the Chinese market and continues to work with regulators and customers.
Operating margins
Expects operating margins of approximately 25% in the second half of 2026.